Senior insider sale
ENLIVEN THERAPEUTICS, INC. — senior position signals high conviction
$709.8K
20K shares
What this filing means
KUNKEL LORI ANNE plans to sell 20K shares of ENLIVEN THERAPEUTICS, INC. valued at approximately $709.8K. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 6/5/2026ACC: 0001974158-26-000072
Director
Since Feb 2026
20K
Shares to sell
$709.8K
Approx. market value
20K
Acquired (3 months)
1
Planned
Securities Acquired — Last 3 Months1
Pre-IPO Shares
N/A
3/12/2020
20KTotal acquired20K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
3/12/2020 | Pre-IPO Shares N/A | 20K | — |
| Total | 20K | ||
Planned & Completed Dispositions1
NasdaqPlanned
Units to sell
20K
Market value
$709.8K
6/5/2026
Total
Units
20K
Value
$709.8K
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
6/5/2026 | 20K | $709.8K | Nasdaq | Planned |
| Total | 20K | $709.8K | ||